Cardiff Oncology Inc (FRA:XE7C)
€ 2.8 0.1 (3.7%) Market Cap: 150.33 Mil Enterprise Value: 95.75 Mil PE Ratio: 0 PB Ratio: 3.01 GF Score: 59/100

Q3 2023 Cardiff Oncology Inc Earnings Call Transcript

Nov 02, 2023 / 08:30PM GMT
Release Date Price: €1.01 (+2.44%)
Operator

Welcome to the Cardiff Oncology third-quarter 2023 financial results and corporate update conference call. (Operator Instructions) As a reminder, this call is being recorded today, November 2, 2023.

I would now like to turn the conference call over to Kiki Patel of Gilmartin Group. Please go ahead.

Kiki Patel
Gilmartin Group LLC - IR

Thank you, operator. Joining us on the call today from Cardiff Oncology are Chief Executive Officer, Mark Erlander, and Chief Financial Officer, Jamie Levine.

During this conference call, management will make forward-looking statements, including without limitations, statements related to guidance, results, and the timing of the area for our advantage and clinical trials.

These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties.

Factors that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot